Online first
Original article
Published online: 2024-06-12
Long-term outcomes following paclitaxel-coated balloons versus thin-strut drug eluting stents for treatment of in-stent restenosis in Chronic Coronary Syndrome (CCS Dragon-Registry)
Pubmed: 38887780
Abstract
Not available
References
- Alfonso F, Coughlan JJ, Giacoppo D, et al. Management of in-stent restenosis. EuroIntervention. 2022; 18(2): e103–e123.
- Kuntz RE, Baim DS. Defining coronary restenosis. Newer clinical and angiographic paradigms. Circulation. 1993; 88(3): 1310–1323.
- Elbadawi A, Dang AT, Mahana I, et al. Outcomes of percutaneous coronary intervention for in-stent restenosis versus de novo lesions: a meta-analysis. J Am Heart Assoc. 2023; 12(13): e029300.
- Wańha W, Bil J, Januszek R, et al. Long-Term outcomes following drug-eluting balloons versus thin-strut drug-eluting stents for treatment of in-stent restenosis (deb-dragon-registry). Circ Cardiovasc Interv. 2021; 14(9): e010868.
- Moussa ID, Mohananey D, Saucedo J, et al. Trends and outcomes of restenosis after coronary stent implantation in the United states. J Am Coll Cardiol. 2020; 76(13): 1521–1531.
- Neumann FJ, Sousa-Uva M, Ahlsson A, et al. ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40(2): 87–165.
- Wolny R, Kowalik I, Januszek R, et al. Long-term outcomes following drug-eluting balloons vs. thin-strut drug-eluting stents for treatment of recurrent restenosis in drug-eluting stents. Kardiol Pol. 2022; 80(7-8): 765–773.
- Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. Eur Heart J. 2015; 36(47): 3320–3331.
- Borovac JA, D'Amario D, Vergallo R, et al. Neoatherosclerosis after drug-eluting stent implantation: a novel clinical and therapeutic challenge. Eur Heart J Cardiovasc Pharmacother. 2019; 5(2): 105–116.
- Baan J, Claessen BE, Dijk KBv, et al. A randomized comparison of paclitaxel-eluting balloon versus everolimus-eluting stent for the treatment of any in-stent restenosis: the DARE trial. JACC Cardiovasc Interv. 2018; 11(3): 275–283.
- Grimfjärd P, Bergman E, Buccheri S, et al. Outcome of PCI with Xience versus other commonly used modern drug eluting stents: A SCAAR report. Catheter Cardiovasc Interv. 2021; 98(2): E197–E204.
- Legutko J, Bryniarski KL, Kaluza GL, et al. Intracoronary imaging of vulnerable plaque-from clinical research to everyday practice. J Clin Med. 2022; 11(22): 6639.
- Byrne RA, Rossello X, Coughlan JJ, et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023; 44(38): 3720–3826.
- Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999; 100(18): 1872–1878.
- Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94(446): 496–509.
- Giacoppo D, Alfonso F, Xu Bo, et al. Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). Eur Heart J. 2020; 41(38): 3715–3728.
- Byrne RA, Neumann FJ, Mehilli J, et al. ISAR-DESIRE 3 investigators. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2013; 381(9865): 461–467.
- Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, et al. RIBS IV Study Investigators (under auspices of Interventional Cardiology Working Group of Spanish Society of Cardiology). A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: the RIBS IV randomized clinical trial. J Am Coll Cardiol. 2015; 66(1): 23–33.
- Cortese B, Silva Orrego P, Agostoni P, et al. Effect of drug-coated balloons in native coronary artery disease left with a dissection. JACC Cardiovasc Interv. 2015; 8(15): 2003–2009.
